Clinical trial

A UK Registry for Metabolic and Bariatric Endoscopic Interventions

Recruiting now · Not applicable · 1 countries · Registry ID NCT06305208

Recruiting nowNot applicableObservational

What this study is about

In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 99 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity, Diabetes Mellitus, Type 2

Full registry criteria

Inclusion Criteria: * Any patient undergoing a primary or revisional bariatric or metabolic endoscopic procedure. * Age ≥ 18 years old * Able to give written informed consent. Exclusion Criteria: * Any bariatric or metabolic endoscopic procedure performed outside the UK. * Any bariatric or metabolic endoscopic procedure not currently listed within the registry protocol or agreed by the steering committee. * Unable to provide written informed consent.

Treatments and study arms

Endoscopic gastric suturing

Device

Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.

Endoscopic gastric plication

Device

Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.

Revisional gastroplasty

Device

Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss

Transoral outlet reduction endoscopy (TORe)

Device

Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.

Duodenal mucosal resurfacing (DMR)

Device

Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.

Intragastric balloon(s)

Device

The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.

Primary outcomes

Total body weight loss percentage (TBWL%)6-months, 1-, 2-, 3-, 5-years

For primary or revisional bariatric procedures: Percentage weight loss will be calculated using the following formula: TBWL% = \[(weight at the baseline-weight at the end of time period)/weight at baseline\] x 100

Change in glycated haemoglobin (HbA1c; mmol/mol)6-months, 1-, 2-, 3-, 5-years

For primary metabolic procedures

Change in the number and dose of anti-diabetic medications6-months, 1-, 2-, 3-, 5-years

For primary metabolic procedures

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Cleveland Clinic London🇬🇧 London, United Kingdom
Benjamin Norton, MDContact
Rehan Haidry, MDPrincipal Investigator